Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Savella’s Launch For Fibromyalgia: Many Sales Forces, Single Claim

Executive Summary

Forest's promotional messaging for the launch of its fibromyalgia drug Savella (milnacipran) has a somewhat unusual emphasis - the product's limited utility

You may also be interested in...

Forest Continues To Bank On Growth Of its Savella Medication for Fibromyalgia

With the only drug indicated solely for fibromyalgia, Forest expects Savella to help offset declining sales from its Lexapro antidepressant.

Offsetting The Pain: Forest Pushes Savella To Dampen A Lexapro Sales Slide

Forest's Savella is gaining 1,200 to 1,300 new prescribers per week and now has a 3.5 percent share of the market for fibromyalgia treatments

Fibromyalgia Market Snapshot: Forest Delays Savella Launch

Forest is delaying the launch of its recently approved fibromyalgia drug Savella (milnacipran) until at least May, when FDA is expected to okay a tablet-color change. Analysts do not anticipate the move will impact the drug's long-term sales when it joins Pfizer's Lyrica and Lilly's Cymbalta on the market

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts